E-polymerase chain reaction. Cancer. 2003;97(11):2887897. 49. Zeltzer PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron-specific enolase in young children with neuroblastoma. Partnership to stage and disease course. Cancer. 1986;57(six):1230234. 50. Riley RD, et al. A systematic evaluation of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10(1 pt 1):42. 51. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An important heparin-binding domain within the fibroblast development issue receptor kinase. Science. 1993;259(5103):1918921. 52. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for higher density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19(two):18593. 53. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003; 31(four):e15. 54. Pei Y, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012;21(two):15567. 55. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression information working with empirical Bayes methods. Biostatistics. 2007;eight(1):11827. 56. Dong M, et al. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest. 2007;117(1):20617. 57. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The form III transforming development factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007; 67(3):1090098. 58. Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol. 2010;42(11):1802807. 59. Mythreye K, Blobe GC. The kind III TGF-beta receptor regulates epithelial and cancer cell migration via beta-arrestin2-mediated activation of Cdc42.Ciprofloxacin Proc Natl Acad Sci U S A.Pentamidine isethionate 2009;106(20):8221226.PMID:24189672 60. Finger EC, Lee NY, You HJ, Blobe GC. Endocytosis with the sort III transforming growth factor-beta (TGF-beta) receptor via the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J Biol Chem. 2008;283(50):348084818. 61. Lambert KE, Huang H, Mythreye K, Blobe GC. The form III transforming development factor-beta receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell. 2011;22(9):1463472.The Journal of Clinical Investigationhttp://www.jci.orgVolumeNumberNovemberresearch article62. Chen W, et al. Beta-arrestin two mediates endocytosis of form III TGF-beta receptor and down-regulation of its signaling. Science. 2003;301(5638):1394397. 63. Blobe GC, et al. Functional roles for the cytoplasmic domain with the variety III transforming growth factor beta receptor in regulating transforming development issue beta signaling. J Biol Chem. 2001;276(27):246274637. 64. Boehm JS, et al. Integrative genomic approaches recognize IKBKE as a breast cancer oncogene. Cell. 2007;129(6):1065079. 65. Meijering E, Jacob M, Sarria JC, Steiner P, Hirling H, Unser M. Design and style and validation of a tool for neurite tracing and evaluation in fluorescence microscopy pictures. Cytometry A. 2004;58(two):16776. 66. Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC. TbetaRIII/beta-arrestin2 regulates integrin alpha5beta1 trafficking, function, and localization in epithelial cells. Oncogene. 2013; 32(11):1416427. 67. Gatza CE, et al. Kind III TGF-beta receptor enhances colon cancer cell migration and anchorage-independent development. Neoplasia. 2011;13(eight):75870. 68. Ochiai H, et.